Literature DB >> 8613233

Poor glycemic control induces hypertension in diabetes mellitus.

M W Brands1, T E Hopkins.   

Abstract

We conducted this study to test the hypothesis that hypertension is a primary consequence of poor glycemic control per se very early in insulin-dependent diabetes mellitus. Sprague-Dawley rats (n=15) were instrumented with artery and vein catheters, placed in metabolic cages, and sodium intake was clamped throughout the study. Mean arterial pressure was measured 24 h/d. After a precontrol period, streptozotocin (70 mg/kg IV) was administered, and 15 hours later a continuous intravenous infusion was begun at 4 U/rat per day. The insulin infusion was titrated on an individual rat basis to maintain good glycemic control, and after this 7-day control period, blood glucose, urinary sodium excretion, and mean arterial pressure were not different from precontrol values, averaging 8.8 +/- 0.6 mmol/L, 2.8 +/- 0.2 mmol/d, and 103 +/- 2 mm/Hg, respectively, for control days 5 through 7. Subsequently, a 4-day period of poor glycemic control was initiated by reducing the insulin infusion rate. Blood glucose, urinary sodium excretion, and mean arterial pressure began to increase on day 1; for diabetes days 3 and 4, they averaged 23.4 +/- 1.0 mmol/L, 3.6 +/- 0.1 mmol/d, and 110 +/- 2 mm Hg, respectively. All were significantly elevated. When insulin treatment was restored, all variables returned to control levels during the next 4 days. A second 4-day diabetic period yielded similar results. These results indicate that elevated blood pressure is a primary consequence of poor glycemic control in insulin-dependent diabetes, occurring before renal injury has had time to develop, and therefore, may be a factor contributing to the initiation of end-organ injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613233     DOI: 10.1161/01.hyp.27.3.735

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  NO- and non-NO-, non-prostanoid-dependent vasodilatation in rat sciatic nerve during maturation and developing experimental diabetic neuropathy.

Authors:  Kirsten Thomsen; Inger Rubin; Martin Lauritzen
Journal:  J Physiol       Date:  2002-09-15       Impact factor: 5.182

2.  Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice.

Authors:  Luminita H Pojoga; Tham M Yao; Lauren A Opsasnick; Amanda E Garza; Ossama M Reslan; Gail K Adler; Gordon H Williams; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2013-11-26       Impact factor: 4.030

3.  The ocular hemodynamic response to nitric oxide synthase inhibition is unaltered in patients with early type I diabetes.

Authors:  Guido T Dorner; Gerhard Garhöfer; Nicole Selenko; Peter Fasching; Michaela Bayerle-Eder; Leopold Schmetterer; Michael Wolzt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-06-26       Impact factor: 3.117

4.  Nutritional correlates and dynamics of diabetes in the Nile rat (Arvicanthis niloticus): a novel model for diet-induced type 2 diabetes and the metabolic syndrome.

Authors:  Fadi Chaabo; Andrzej Pronczuk; Ekaterina Maslova; Kc Hayes
Journal:  Nutr Metab (Lond)       Date:  2010-04-15       Impact factor: 4.169

5.  Noninvasive transcutaneous sampling of glucose by electroporation.

Authors:  S Srinivasa Murthy; V Siva Ram Kiran; S K Mathur; S Narasimha Murthy
Journal:  J Diabetes Sci Technol       Date:  2008-03

6.  Blood Pressure Control among Hypertensive Diabetic Patients on Follow-Up at Chronic Clinic of Nekemte Referral Hospital in West Ethiopia.

Authors:  Mohammed Gebre Dedefo; Dureti Bayisa Gemechu; Ginenus Fekadu; Tesfa Tekle Dibessa
Journal:  Int J Hypertens       Date:  2020-06-19       Impact factor: 2.420

7.  Cardiopulmonary Profile in Streptozotocin-Induced Type 1 Diabetic Rats during Systemic Endotoxemia.

Authors:  Ching-Hsia Hung; Che-Ning Chang; Yu-Wen Chen; Yu-Chung Chen; Jann-Inn Tzeng; Jhi-Joung Wang
Journal:  J Diabetes Res       Date:  2013-02-25       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.